Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-02-04
2011-12-06
Young, Shawquia (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S147000
Reexamination Certificate
active
08071617
ABSTRACT:
The present invention provides compounds having formula (I):and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
REFERENCES:
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5149780 (1992-09-01), Plow et al.
patent: 5288854 (1994-02-01), Diamond et al.
patent: 5298492 (1994-03-01), Neustadt et al.
patent: 5340800 (1994-08-01), Liu et al.
patent: 5397791 (1995-03-01), Hartman et al.
patent: 5424399 (1995-06-01), Arnaout
patent: 5470953 (1995-11-01), Gallatin et al.
patent: 5585359 (1996-12-01), Breslin et al.
patent: 5597567 (1997-01-01), Whitcup et al.
patent: 5936089 (1999-08-01), Carpino et al.
patent: 5973188 (1999-10-01), Alig et al.
patent: 6204280 (2001-03-01), Gante et al.
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6331640 (2001-12-01), Fotouhi et al.
patent: 6340679 (2002-01-01), Peyman et al.
patent: 6358976 (2002-03-01), Wityak et al.
patent: 6515124 (2003-02-01), Fotouhi et al.
patent: 6524581 (2003-02-01), Adamis
patent: 6605597 (2003-08-01), Zablocki et al.
patent: 6653478 (2003-11-01), Urbanski et al.
patent: 6667318 (2003-12-01), Burdick et al.
patent: 6670321 (2003-12-01), Adamis
patent: 6803384 (2004-10-01), Fotouhi et al.
patent: 6872735 (2005-03-01), Burdick et al.
patent: 7211586 (2007-05-01), Fenton et al.
patent: 2002/0115692 (2002-08-01), Archibald et al.
patent: 2002/0119994 (2002-08-01), Burdick et al.
patent: 2002/0132807 (2002-09-01), Wang et al.
patent: 2002/0177591 (2002-11-01), O'Donnell et al.
patent: 2003/0044406 (2003-03-01), Dingivan
patent: 2003/0068320 (2003-04-01), Dingivan
patent: 2003/0166630 (2003-09-01), Auvin et al.
patent: 2004/0006236 (2004-01-01), Fotouhi et al.
patent: 2004/0028648 (2004-02-01), Adamis
patent: 2004/0038973 (2004-02-01), Nahra et al.
patent: 2004/0058968 (2004-03-01), Burdick et al.
patent: 2004/0120960 (2004-06-01), Jardieu et al.
patent: 2004/0122047 (2004-06-01), Felton et al.
patent: 2005/0080119 (2005-04-01), Fotouhi et al.
patent: 2006/0281739 (2006-12-01), Gadek et al.
patent: 2008/0176896 (2008-07-01), Shen et al.
patent: 2008/0182839 (2008-07-01), Shen et al.
patent: 2009/0155176 (2009-06-01), Burnier et al.
patent: 2010/0092541 (2010-04-01), Burnier et al.
patent: 2010/0092542 (2010-04-01), Burnier et al.
patent: 2010/0093693 (2010-04-01), Shen et al.
patent: 314863 (1989-05-01), None
patent: 362526 (1990-04-01), None
patent: 362531 (1990-04-01), None
patent: 0656789 (1997-12-01), None
patent: 4193895 (1992-07-01), None
patent: WO 90/03400 (1990-04-01), None
patent: WO 90/10652 (1990-09-01), None
patent: WO 90/13316 (1990-11-01), None
patent: WO 91/19511 (1991-12-01), None
patent: WO 92/03473 (1992-03-01), None
patent: WO 94/03481 (1994-02-01), None
patent: WO 94/11400 (1994-05-01), None
patent: WO 95/04531 (1995-02-01), None
patent: WO 95/28170 (1995-10-01), None
patent: WO 96/09836 (1996-04-01), None
patent: WO 98/46599 (1998-10-01), None
patent: WO 99/49856 (1999-10-01), None
patent: WO 99/49856 (1999-11-01), None
patent: WO 00/21920 (2000-04-01), None
patent: WO 00/38714 (2000-07-01), None
patent: WO 00/44731 (2000-08-01), None
patent: WO 01/27102 (2001-04-01), None
patent: WO 01/58853 (2001-08-01), None
patent: WO 01/87840 (2001-11-01), None
patent: WO 02/50080 (2002-06-01), None
patent: WO 02/059114 (2002-08-01), None
patent: WO 02/098426 (2002-12-01), None
patent: WO 2004/026406 (2004-04-01), None
patent: WO 2005/014533 (2005-02-01), None
patent: WO 2005/014533 (2005-04-01), None
patent: WO 2005/044817 (2005-05-01), None
Boschelli, et al. 3-Alkoxybenzo[b]thiophene-2-carboxamides as inhibitors of neutrophil-endothelial cell adhesion. J Med Chem. 1994; 37(6): 717-8.
Boschelli, et al. Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-mediated cell adhesion by benzo[b]thiophene-, benzufuran-, indole-, and naphthalene-2-carboxamides: Identification of PD 144795 as an antiinflammatory agent. J Med Chem. 1995; 38: 4597-614.
Burdick, et al. N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: Structure-activity relationship of the benzoyl moiety. Bioorganic & Medicinal Chemistry Letters. 2004; 14(9): 2055-9.
Burdick, et al. N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship. Bioorganic & Medicinal Chemistry Letters. 2004; 13(6): 1015-8.
Chang, et al. Effects of pharmacologic agents on the reversed passive Arthus reaction in the rat. Eur J Pharmacol. 1981; 69(2): 155-64.
International Search Report from corresponding International Application No. PCT/US2004/036942.
Cosimi, et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol. 1990; 144(12): 4604-12.
Definition of Lupus erythematorsus. Retrieved on Dec. 28, 2006. Retrieved from the Internet URL: http://en.wikipedia.org/wiki/Lupus—erythematorsus.
Diamond et al. The Dynamic regulation of integrin adhesiveness. Current Biology. 1994; 4(6): 506-532.
Fischer, et al. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation. The Lancet. 1986; 2: 1058-60.
Gadek, et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 2002; 295: 1086-9.
Gao, et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp Eye Res. Apr. 2004;78(4):823-35.
Gorski, A. The role of cell adhesion molecules in immunopathology. Immunology Today. 1994; 15: 251-5.
Hildreth, et al. Monoclonal antibodies against porcine LFA-1: Species cross-reactivity and functional effects of β-subunit-specific antibodies. Molecular Immunology. 1989; 26(9): 883-95.
Huang, et al. A binding interface of the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J Biological Chemistry. 1995; 270(32): 19008-16.
Kavanaugh, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994; 37(7): 992-1004.
Keating, et al. Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alphal subunit of lymphocyte function-associated antigen-1. Protein Sci. 2006; 15(2):290-303.
Keating, et al. Putting the pieces together : Contribution of fluorescence polarization assays to small molecule lead optimization. Proc. SPIE. 2000; vol. 3913, p. 128-137. (Online Publication Date: Jul. 2, 2003).
Kishimoto, et al. Integrins, ICAMs, and selectins: Role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv Pharmacol. 1994; 25: 117-69.
Klausner, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res. 2003; 20(9): 1466-73.
Le Mauff, et al. Effect of anti-LFA1 (CD11a) monoclonal antibodies in acute rejection of human kidney transplantation. Transplantation. 1991; 52(2): 291-5.
Liebeskind, D. S. Paraneoplastic encephalopyelitis. eMedicine. Updated Jun. 11, 2009. Available at http://emedicine.medscape.com/article/1157060. Accessed Dec. 29, 2009.
Liu, G. Inhibitors of LFA-1/ICAM-1 interaction: from monoclonal antibodies to small molecules. Drugs of the Future. 2001; 26: 767-78.
Liu, G. Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin Ther Patents. 2001; 11: 1383-93.
Lu, et al. The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of the integrin LFA-1. J Immunol. 2004; 173: 3972-8.
Lupus erythematosus (online), retrieved on Dec. 28, 2006. Retrieved from the interne
Barr Kenneth
Oslob Johan D.
Shen Wang
Zhong Min
SARcode Bioscience Inc.
Wilson Sonsini Goodrich & Rosati
Young Shawquia
LandOfFree
Modulators of cellular adhesion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of cellular adhesion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of cellular adhesion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4267447